Direct sales through a local subsidiary in Canada
Remsima SC (photo courtesy of Celltrion Healthcare)湲 蹂肄
[아시아경제 김지희 기자] Celltrion Healthcare announced on the 8th that it has launched ‘Remsima SC (ingredient: Infliximab)’, a subcutaneous injection-type biopharmaceutical for the treatment of autoimmune diseases in Canada.
Celltrion Healthcare obtained approval from the Canadian Ministry of Health in January to sell Remsima SC for rheumatoid arthritis (RA) indications. In addition, with a plan to directly sell Remsima SC in Canada, it has been expanding marketing and sales personnel belonging to its Canadian subsidiary. AbbVie and BMS also made efforts to recruit talent, such as hiring a sales director, Joban Antunovich.
According to IQVIA, a pharmaceutical market research firm, the Canadian autoimmune disease treatment (TNF-α inhibitor) market is worth about 2 trillion won as of 2020. In particular, in Canada, unlike other regions, infliximab accounts for half of the TNF-α inhibitor market. In the case of Remsima IV formulation, it recorded a market share of 16% in Canada (based on IQVIA in the fourth quarter of 2020) and is growing steadily. Accordingly, Celltrion Healthcare expects that Remsima SC will achieve stable prescription expansion through synergy with IV formulations.
Celltrion Healthcare plans to quickly settle into the market from the beginning by strengthening customized marketing activities for major stakeholders who have an influence on Remsima SC prescription, such as medical staff, patients, hospitals, and insurance companies. To this end, we are operating the ‘Patient Support Program (PSP)’, which provides a prescription guide for Remsima SC, guides the insurance reimbursement process, and supports the convenience of patients throughout the entire drug administration process. In addition, a customized sales strategy is underway that reflects the characteristics of the Canadian pharmaceutical market, such as promoting ABM (Advisory Board Meeting) for doctors and patients, and expanding meetings with major patient associations.
Edward Keystone, a professor at the University of Toronto Medical School in Canada, said, “Rheumatoid arthritis is a chronic inflammatory autoimmune disease that can cause irreversible joint damage if not treated properly. As more flexible management becomes possible, patients will be able to manage their own treatment status more efficiently.”
An official from Celltrion Healthcare said, “As Remsima SC entered Canada, the second largest TNF-α inhibitor market in the world, it has entered the North American market in earnest beyond the existing European region.” Following this, as Remsima SC is scheduled to be released in Australia in the third quarter of this year, we will focus on expanding the market so that prescriptions can be made all over the world.”
By Kim Ji-hee, reporter [email protected]
Source: 아시아경제신문 실시간 속보 by www.asiae.co.kr.
*The article has been translated based on the content of 아시아경제신문 실시간 속보 by www.asiae.co.kr. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!
*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.
*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!